Plasma integrated concentration of growth hormone after recombinant human growth hormone injection. Implications for determining an optimal dose
S. A. Chalew, M. Phillip and A. A. Kowarski
Division of Pediatric Endocrinology, University of Maryland School of Medicine, Baltimore 21201.
OBJECTIVE--To evaluate the effect of a standard dose of injected
recombinant growth hormone on the integrated concentrations of growth
hormone and insulin. DESIGN--Integrated concentrations were studied in
patients receiving growth hormone therapy before and on the day of
injection. SETTING--Pediatric endocrine clinic and diagnostic unit.
PATIENTS--Twelve growth hormone-deficient patients with poor linear growth
and deficient growth hormone response to provocative stimulation and/or
24-hour integrated concentration. INTERVENTION--Patients received
subcutaneous injections of 0.06 mg/kg of growth hormone three times a week
in the evenings at approximately 8 PM. Integrated concentrations were
measured again approximately 6 months after the start of therapy at the
time of a growth hormone injection. MEASUREMENTS AND RESULTS--Mean growth
hormone dose administered was 2.0 +/- 0.5 mg. Integrated concentration of
growth hormone was 2.2 +/- 0.9 micrograms/L before therapy. The integrated
concentration of growth hormone after treatment (14.6 +/- 4.2 micrograms/L)
was significantly higher than that before treatment and that of normally
growing children (P < .001). After injection, peak growth hormone level
was 53.7 +/- 24.1 micrograms/L; time to peak growth hormone level, 4.8 +/-
1.2 hours; constant of elimination, 0.24 +/- 0.06 per hour; half life, 3.0
+/- 0.7 hours; area under the curve, 328 +/- 85 (microgram.h)/L; clearance
rate, 107.6 +/- 34.3 mL/min (3.2 +/- 0.8 mL/min per kilogram based on
weight, 95.2 +/- 24.2 mL/min per meter squared based on surface area).
There was no relationship between integrated concentration of growth
hormone or pharmacokinetic variables after treatment and the growth
response to 6 months' therapy. Integrated concentration of insulin before
treatment was 19.0 +/- 10.9 mU/L, which was significantly lower than that
after injection of growth hormone (33.4 +/- 9.5 mU/L; n = 9, P < .0008).
CONCLUSIONS--Integrated concentrations of growth hormone after an injection
of 0.06 mg/kg of growth hormone are considerably higher than spontaneous
integrated concentrations of growth hormone observed in normally growing
children, and associated with a rise in insulin secretion. These changes
may be pertinent in patients with underlying insulin resistance or when
higher doses of growth hormone are used for therapy.